Advances in Cancer Research: Aeg-1/Mtdh/Lyric Implicated in Multiple Human Cancers Volume 120

ISBN-13: 9780124016767 / Angielski / Twarda / 2013 / 264 str.

Devanand Sarkar

Opis

Advances in Cancer Research provides invaluable information on the exciting and fast-moving field of cancer research. Here, once again, outstanding and original reviews are presented on a variety of topics. This volume covers AEG-1/MTDH/Lyric implicated in multiple human cancers.

• Provides information on cancer research
• Outstanding and original reviews
• Suitable for researchers and students

Recenzje

Praise for the Serial"This classic and essential series presents critical overviews on select aspects of both cancer research and the basic underlying sciences." --American Scientist"Excellent, highly informative, in-depth reviews.expertly written, up-to-date, and well-referenced." --Journal of Medicinal Chemistry"This is a series that has a long tradition of excellence in the field of cancer biology." --Doody's Publishing Reviews

Spis treści

1. AEG-1/MTDH/LYRIC the Beginning: Initial Cloning, Structure, Expression Profile, and Regulation of Expression2. AEG-1/MTDH/LYRIC: Clinical Significance3. AEG-1/MTDH/LYRIC: Signaling Pathways, Downstream Genes, Interacting Proteins, and Regulation ofTumor Angiogenesis4. Pleiotropic Roles of Metadherin/AEG-1 in Breast Cancer5. Drug Resistance Mediated by MTDH/AEG-1/Lyric6. The Role of AEG-1/MTDH/LYRIC in the Pathogenesis of Central Nervous System Disease7. AEG-1/MTDH/LYRIC in Liver Cancer

O autorze

Dr. Sarkar received his MBBS from Dhaka Medical College, Bangladesh and PhD from Nagoya University, Japan. After postdoctoral training in Columbia University, NY he joined Virginia Commonwealth University (VCU) as a faculty where he is now a Professor in the Department of Human and Molecular Genetics, and Associate Director of Education and Training at Massey Cancer Center. Dr. Sarkar's research focuses on identifying novel regulators of hepatocellular carcinoma (HCC), especially obesity-induced HCC, and developing targeted gene- and immunotherapy based on the accrued knowledge. Dr. Sarkar has published more than 280 papers and his research is funded by NCI, NIDDK and DOD. Paul B. Fisher, MPh, PhD, FNAI, Professor and Chairman, Department of Human and Molecular Genetics, Director, VCU Institute of Molecular Medicine Thelma Newmeyer Corman Chair in Cancer Research in the VCU Massey Cancer Center, VCU, School of Medicine, Richmond, VA, and Emeritus Professor, Columbia University, College of Physicians & Surgeons, New York, NY. Dr. Fisher is among the top 10% of NIH funded investigators over the past 35-years, published approximately 625 papers and reviews, and has 55 issued patents. He pioneered novel gene/discovery approaches (subtraction hybridization), developed innovative therapeutic approaches (Cancer Terminator Viruses), presented numerous named and distinguished lectures, founded several start-up companies, was Virginia Outstanding Scientist of 2014 and elected to the National Academy of Inventors in 2018. Dr. Fisher is a prominent nationally and internationally recognized cancer research scientist focusing on understanding the molecular and biochemical basis of cancer development and progression to metastasis and using this garnered information to develop innovative approaches for diagnosing and treating cancer. He discovered and patented novel genes and gene promoters relevant to cancer growth control, differentiation and apoptosis. His discoveries include the first cloning of p21 (CDK inhibitor), human polynucleotide phosphorylase, mda-9/syntenin (a pro-metastatic gene), mda-5 and mda-7/IL-24, which has shown promising clinical activity in Phase I/II clinical trials in patients with advanced cancers. Dr. Fisher alsohas a documented track record as a successful seasoned entrepreneur. He was Founder and Director of GenQuest Incorporated, a functional genomics company, which merged with Corixa Corporation in 1998, traded on NASDAQ and was acquired by GlaxoSmithKline in 2006. He discovered the cancer-specific PEG-Prom, which is the core technology of Cancer Targeting Systems (CTS, Inc.), a Virginia/Maryland-based company (at Johns Hopkins Medical Center) focusing on imaging and therapy ("theranostics”) of metastatic cancer (2014) by Drs. Fisher and Martin G. Pomper. He co-founded InVaMet Therapeutics (IVMT) and InterLeukin Combinatorial Therapies (ILCT) with Dr. Webster K. Cavenee (UCSD) (2017/2018).